Designing Programmable Peptide Nucleic Acid-based Nanovaccines for Anticancer Immune Activation.

Area of Science:

• Biotechnology and Nanomedicine
• Immunology and Cancer Research

Background:

• Developing cancer vaccines that deliver antigens and adjuvants to immune cells without causing excessive inflammation is a significant hurdle.
• Targeted delivery systems are crucial for enhancing vaccine efficacy and minimizing off-target effects in cancer immunotherapy.

Purpose of the Study:

• To develop and evaluate a versatile peptide nucleic acid (PNA)-based vaccine nanoplatform (PVN) for robust anti-tumor immune responses.
• To investigate the targeting capabilities and immune-stimulating properties of the PVN in a syngeneic melanoma model.

Main Methods:

• Constructed a PNA-based vaccine nanoplatform (PVN) using an 11-mer PNA scaffold for one-pot loading of antigenic peptide (SIINFEKL), CpG adjuvant, and LLP2A targeting ligand.
• Utilized super-resolution fluorescence imaging and circular dichroism spectroscopy to analyze the nanoplatform's structure and component interactions.
• Assessed anti-tumor efficacy in a B16-OVA syngeneic melanoma mouse model, evaluating immune cell responses and tumor regression.

Main Results:

• The PVN successfully co-loaded antigenic peptide, adjuvant, and targeting ligand, demonstrating specific spatial arrangement and PNA strand binding.
• The LLP2A ligand on PVNs targeted activated α4β1 integrin on immune and melanoma cells, enhancing antigen presentation by dendritic cells.
• PVN treatment significantly boosted CD8+ T cell and natural killer cell responses, leading to substantial tumor regression and prolonged survival in mice.

Conclusions:

• The PNA-based vaccine nanoplatform (PVN) is a highly versatile and programmable system for eliciting potent anti-tumor immunity.
• The modular design allows for the convenient assembly of various components, making PVN a practical platform for personalized cancer vaccine development.
• PVN demonstrates significant potential for advancing cancer vaccine strategies through targeted delivery and enhanced immune stimulation.